Селиверстов Е.И., Лобастов К.В., Илюхин Е.А. и др. Профилактика, диагностика и лечение тромбоза глубоких вен. Рекомендации российских экспертов. Флебология. 2023;17(3):152–296. [Seliverstov E.I., Lobastov K.V., Ilyukhin E.A. et al. Prevention, diagnosis and treatment of deep vein thrombosis. Recommendations of Russian experts. J Venous Disorders. 2023;17(3):152–296. doi: 10.17116/flebo202317031152..
DOI: 10.17116/flebo202317031152

Heit J.A., Spencer F.A., White R.H. The epidemiology of venous thromboembolism. J Thromb. Thrombolysis. 2016;41(1):3–14.

Мельников М.А., Яровенко Г.В., Каторкин С.Е. Эффективность перехода со стандартной антикоагулянтной терапии в лечении пациентов, перенесших тромбоз глубоких вен в системе нижней полой вены. Русский медицинский журнал. 2019;8(II):98–102. [Melnikov M.A., Yarovenko G.V., Katorkin S.E. Efficiency of transition from standard anticoagulant therapy in the treatment of patients with deep vein thrombosis in the inferior vena cava system. Russian Medical Journal. 2019;8(II):98–102. (In Russ.)].

Ortel T.L., et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–738. doi: 10.1182/bloodadvances.2020001830..
DOI: 10.1182/bloodadvances.2020001830

Миронов А.В., Леонтьев С.Г., Мамадумаров В.А., Устинов Ф.С. Вторичная профилактика ВТЭО: современный взгляд. Русский медицинский журнал. 2014;17:1254. [Mironov A.V., Leontyev S.G., Mamadumarov V.A., Ustinov F.S. Secondary prevention of VTEC: a modern view. Russian Medical Journal. 2014;17:1254. (In Russ.)].

Khan F., et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363. doi: 10.1136/bmj.l4363..
DOI: 10.1136/bmj.l4363

Kearon C., et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480–83. doi: 10.1111/jth.13336..
DOI: 10.1111/jth.13336

Konstantinides S.V., Meyer G., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J. 2019;54(3). doi:10.1183/13993003.01647-2019..
DOI: 10.1183/13993003.01647-2019

Kakkos S., Gohel M., Baekgaard N. Editor’s Choice ‒ European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc. 2021;61(1):9–82. doi: 10.1016/j.ejvs.2020.09.023..
DOI: 10.1016/j.ejvs.2020.09.023

Schulman S., et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Thrombolysis. 2006;4(4):734–42. doi: 10.1111/j.1538-7836.2006.01795.x..
DOI: 10.1111/j.1538-7836.2006.01795.x

van Dongen C.J.J., et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med. 2003;163(11):1285–93. doi: 10.1001/archinte.163.11.1285..
DOI: 10.1001/archinte.163.11.1285

Ensor J., et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ. Open. 2016;6(5):e011190. doi: 10.1136/bmjopen-2016-011190..
DOI: 10.1136/bmjopen-2016-011190

Tosetto A., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019–25. doi: 10.1111/j.1538-7836.2012.04735.x..
DOI: 10.1111/j.1538-7836.2012.04735.x

Eichinger S., Heinze G., Jandeck L.M., Kyrle P.A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630–36. doi: 10.1161/CIRCULATIONAHA.109.925214..
DOI: 10.1161/CIRCULATIONAHA.109.925214

Jiang Q.-J., et al. Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018;9:876. doi: 10.3389/fphar.2018.00876..
DOI: 10.3389/fphar.2018.00876

Carroll B.J., Piazza G., Goldhaber S.Z. Expand Sulodexide in venous disease. J Thromb Haemost. 2019;17(1):31–8. doi: 10.1111/jth.14324..
DOI: 10.1111/jth.14324

Munari A.C., Cantu S.O., Huet N.E., Alfaro M.A. Could Sulodexide be Helpful in COVID-19. MedDocs Publishers. 2021;946(3). URL: https://annals-of-cardiology-and-vascular-medicine/could-sulodexide-behelpful-in-COVID-19.pdf.https://annals-of-cardiology-and-vascular-medicine/could-sulodexide-behelpful-in-COVID-19.pdf

Li T., Liu X., Zhao Z., et al. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget. 2017;8(2):91351. doi: 10.18632/oncotarget.20518..
DOI: 10.18632/oncotarget.20518

Каторкиню С.Е., Мельников М.А., Кравцов П.Ф. Эффективность Сулодексида в лечении пациентов с хроническими заболеваниями вен нижних конечностей С1-С3 клинических классов по СЕАР. Амбулаторная хирургия. 2019;(3):38–44. [Katorkin S.E., Melnikov M.A., Kravtsov P.F. Sulodexide efficacy in the treatment of patients with chronic lower limb vein diseases of C1-C3 clinical classes according to CEAP. Ambulatornata Khirurgiya. 2019;(3):38–44. (In Russ.)]. doi: 10.21518/1995-1477-2019-1-2-38-44..
DOI: 10.21518/1995-1477-2019-1-2-38-44

Богачев В.Ю., Голованова О.В., Малышева И.Н. Эффективность сулодексида при лечении хронической венозной недостаточности. Результаты исследования ACCORD. Ангиология и сосудистая хирургия. 2017;3(23):83–6. [Bogachev V.Yu., Golovanova O.V., Malysheva I.N. Efficacy of sulodexide in treatment of chronic venous insufficiency. Results of the ACCORD trial. Angiology AND Vascular Surgery. 2017;3(23):83–6. (In Russ.)].

Pompilio G., Integlia D., Raffetto J., Palareti G. Comparative efficacy and safety of sulodexide and other extended anticoagulation treatments for prevention of recurrent venous thromboembolism: a Bayesian network meta-analysis. Open. 2020;4(2):е80–93. doi: 10.1055/s-0040-178..
DOI: 10.1055/s-0040-178

Зудин А.М., Шаповал А.С. Сулодексид в терапии посттромботической болезни, осложнившейся развитием трофических дефектов нижних конечностей, у пациентов, перенесших пневмонию при COVID-19. Атеротромбоз. 2021;(1):41–50. [Zudin A.M., Shapoval A.S. Sulodexide in the treatment of post-thrombotic disease complicated by the development of trophic defects of the lower extremities in patients who had pneumonia with COVID-19. Atherothrombosis. 2021;(1):41–50. (In Russ.)]. doi: 10.21518/2307-1109- 202111-1-41-50..
DOI: 10.21518/2307-1109- 202111-1-41-50

Lasierra C., Granado P. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006;57(1):53–64. doi: 10.1177/000331970605700108..
DOI: 10.1177/000331970605700108

Онучин П.Г. Применение Сулодексида при продленной терапии у больных с венозными тромбозами. Флебология. 2022;(2–2):21. [Onuchin P.G. The use of sulodexide in prolonged therapy in patients with venous thrombosis. J Venous Disorders. 2022;(2–2):21. (In Russ.)].

Морозов А.М., Аванесян А.Э., Болтик А.А., Сергеев А.Н. Возможности применения сулодексида в клинической практике. Медицинский совет. 2023;17(6):289–98. [Morozov A.M., Avanesyan A.E., Boltik A.A., Sergeev A.N. Possibilities of using sulodexide in clinical practice. Meditsinskii sovet. 2023;17(6):289–98. (In Russ.)]. doi: 10.21518/ms2022-050..
DOI: 10.21518/ms2022-050

Andreozzi G.M., et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism. Circulation. 2015;132(20):1891–97. doi: 10.1161/CIRCULATIONAHA.115.016930..
DOI: 10.1161/CIRCULATIONAHA.115.016930

Илюхин Е.А., Пиханова Ж.М. Анализ результатов применения пероральной формы сулодексида у пациентов с посттромботической болезнью и хронической венозной недостаточностью (С3–С4, Es) в рамках наблюдательного исследования ALLEGRO. Флебология. 2021;15(1):24–32. [Ilyukhin E.A., Pikhanova Zh.M. Oral Sulodexide in Patients with Postthrombotic Syndrome and Chronic Venous Insufficiency (C3-C4, Es): a Subanalysis of Data from the Observational Study ALLEGRO. J Venous Disorders. 2021;15(1):24 32. (In Russ.)]. doi: 10.17116/flebo20211501124..
DOI: 10.17116/flebo20211501124

Гусев Л.Л., Леонтьев С.Г., Андрияшкин В.В., Золотухин И.А. Профилактика рецидива тромбоза глубоких вен нижних конечностей. Флебология. 2011;5(4):72–8. [Gusev L.L., Leont’ev S.G., Andriyashkin V.V., Zolotukhin I.A. Prevention of relapses of deep vein thrombosis in the lower extremities (a literature review). J Venous Disorders. 2011;5(4):72–8. (In Russ.)].

Rodger M.A., Kahn S.R., Le Gal G., et al. Inter-observer reliability of measures to assess the post-thrombotic syndrome. J. Thromb Haemost. 2008;100(1):164–66. doi: 10.1160/TH07-11-0678..
DOI: 10.1160/TH07-11-0678

Carroll B.J., Piazza G., Goldhaber S.Z. Sulodexide in venous disease. J Thromb Haemost. 2019;17(1):31–8. doi: 10.1111/jth.14324..
DOI: 10.1111/jth.14324

Saviano M., Maleti O., Liguori L. Double-blind, double-dummy randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin Informa Healthcare. 1993;13(2):96–108. doi: 10.1185/03007999309111538..
DOI: 10.1185/03007999309111538

Ochoa A.G. Sulodexide and phlebotonics in the treatment of venous ulcer. Int Angiol. 2017;36(1):82–7. doi: 10.23736/S0392-9590.16.03718-4..
DOI: 10.23736/S0392-9590.16.03718-4

Bignamini A.A., Matuska J. Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis. Adv Ther. 2020;37(3):1013–33. doi: 10.1007/s12325-020-01232-1..
DOI: 10.1007/s12325-020-01232-1